The Role and Therapeutic Potential of Non-coding RNAs in Resistance to EGFR-TKIs targeted therapy for Non-small Cell Lung Cancer

Yang Zhang; Ye Chen; Li-Li Lu; Xiu-Li Xie; Ren Huan; Li-Fang Wu; Li-Na Tan; Tao Xu; Yong Jin

doi:10.2174/0109298673275752231219080500

The Role and Therapeutic Potential of Non-coding RNAs in Resistance to EGFR-TKIs targeted therapy for Non-small Cell Lung Cancer

Curr Med Chem. 2024 Feb 16. doi: 10.2174/0109298673275752231219080500. Online ahead of print.

Authors

Yang Zhang^{1

2}, Ye Chen³, Li-Li Lu^{1

2}, Xiu-Li Xie^{1

2}, Ren Huan^{1

2}, Li-Fang Wu^{1

2}, Li-Na Tan^{1

2}, Tao Xu^{1

2}, Yong Jin^{1

2}

Affiliations

¹ Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, School of Pharmacy, Anhui Medical University, 230032, Hefei, China.
² Inflammation and Immune-Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Hospital of Anhui Medical University, Anhui Medical University, 230032, Hefei, China.
³ School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.

PMID: 38375847
DOI: 10.2174/0109298673275752231219080500

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide, of which non-small cell lung cancer (NSCLC) is the most common type, and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used for the treatment of NSCLC. EGFR-TKIs are known to develop a drug-resistant response after a certain number of cycles of dosing, and how to alleviate or even reverse EGFR-TKI resistance is an urgent problem at present. This review focuses on the role of ncRNAs in the resistance of NSCLC to EGFR-TKIs and the potential mechanisms underlying the development of NSCLC resistance to EGFR-TKIs. NcRNAs are involved in NSCLC resistance to EGFR-TKIs by mediating cellular drug efflux, epithelial-mesenchymal transition, apoptosis, autophagy, and EGFR mutation. ncRNAs play a crucial role in NSCLC resistance to EGFR-TKIs. Hopefully, the results will provide some guidance and help for the treatment and prognosis of NSCLC.

Keywords: EGFR-TKIs; Non-coding ribonucleic acid (ncRNA); chemoresistance; drug resistance mechanisms; ncRNA-based therapy.; non-small cell lung cancer (NSCLC).